Johnson & Johnson (JNJ, Financial) is set to unveil significant findings from its oncology research at the upcoming American Urological Association (AUA) 2025 Annual Meeting, scheduled for April 26-29 in Las Vegas. A highlight of the event will be data from the 12-month duration of response in the Phase 2b Cohort 2 SunRISe-1 study, which assesses TAR-200, an innovative gemcitabine delivery system for high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guerin (BCG) therapy.
The results are anticipated during the "Practice-changing, Paradigm-shifting Clinical Trials in Urology" session on April 26. Bladder cancer remains a prevalent global health concern, affecting about a million people annually. Though treatments have made strides, conventional methods haven't significantly evolved over the past four decades, often leaving patients who do not respond to initial BCG treatment with few options.
The TAR-200 system provides a localized and sustained release of medication directly into the bladder's tissue, and in pre-clinical studies, it has shown promising penetration capabilities. Additionally, the conference will feature initial outcomes from Cohort 4 of the SunRISe-1 study, which explores TAR-200 as a stand-alone therapy in patients with papillary-only bladder cancer unresponsive to BCG. Due to complications and patient conditions, bladder removal is a challenging standard treatment, but TAR-200 offers a non-invasive alternative.
Moreover, presentations will cover ongoing Phase 3 trials, including the MoonRISe-1 and SunRISe-5 studies, which evaluate the efficacy of TAR-200 and TAR-210 compared to traditional chemotherapy options. These trials aim to address the urgent need for more effective treatments for bladder cancer patients facing limited options.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for Johnson & Johnson (JNJ, Financial) is $170.64 with a high estimate of $185.00 and a low estimate of $150.00. The average target implies an upside of 8.03% from the current price of $157.95. More detailed estimate data can be found on the Johnson & Johnson (JNJ) Forecast page.
Based on the consensus recommendation from 26 brokerage firms, Johnson & Johnson's (JNJ, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Johnson & Johnson (JNJ, Financial) in one year is $188.92, suggesting a upside of 19.61% from the current price of $157.95. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Johnson & Johnson (JNJ) Summary page.
